The sea and medicine, Miaco Kang Innovative Board IPO has been accepted for review.

Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. (referred to as Haihe Pharmaceutical) and Chengdu Maikokang Biotechnology Co., Ltd. (referred to as Maikokang) have had their IPO applications accepted by the Shanghai Stock Exchange's Sci-Tech Innovation Board. The sponsoring institutions are Sinolink and CICC, with planned fundraising amounts of 2.9 billion yuan and 2.929 billion yuan respectively. The prospectus shows that Haihe Pharmaceutical is a high-tech enterprise focused on the discovery, development, production, and commercialization of innovative drugs, with a focus on unmet clinical needs and disease development scientific mechanisms. The company's business has expanded from malignant tumors such as non-small cell lung cancer, gastric cancer, and breast cancer to the treatment of non-malignant tumors such as vascular malformations and excessive growth syndrome, extending from rare diseases to major diseases, demonstrating the company's innovative extension and scientific layout capabilities. Haihe Pharmaceutical has achieved globally competitive breakthroughs in multiple key treatment areas. Risorinib mesylate tablets (CYH33) is the world's first monotherapy targeted treatment drug for post-chemotherapy progression in ovarian clear cell carcinoma (OCCC), and has achieved international leadership in the PRVM/PROS indication; Gomeitinib tablets (SCC244) is the first domestically approved first-line treatment drug for METex14 skipping mutation non-small cell lung cancer (NSCLC); Epimetasitapine (HH2853) is the first domestically developed dual EZH1/2 targeting inhibitor; Paclitaxel oral solution (RMX3001) as the world's only oral form of paclitaxel drug, has established distinct clinical characteristics in terms of efficacy, safety, and ease of use. Maikokang Biotechnology was founded in 2016 and is a biopharmaceutical company dedicated to the research, production, and commercialization of innovative vaccines and novel adjuvants. Maikokang Biotechnology is a market leader in the field of innovative vaccine adjuvant research and development in China. Novel vaccine adjuvants are the "core technology" of innovative vaccine research and development, helping to promote more innovative vaccine research and development, enhance reserves for major public health events, and have strategic significance in terms of industry chain security. Additionally, novel adjuvant technology is recognized as the core technology for developing innovative vaccines and is currently a bottleneck in China's development in this area. The "14th Five-Year Plan for the Development of the Pharmaceutical Industry" explicitly supports directions such as "new vaccine adjuvants" in the context of industrial technology breakthroughs and vaccine supply system construction.